



The Derm Centre

Dr. Victoria Taraska, MD, FRCP

CURRICULUM VITAE

**Last Updated July 2013*

Medical Dermatology
Cosmetic Dermatology
Lasers
Botox®
Fillers
Skin Care

POST GRADUATE EDUCATION

Pre-Medical Training:	University of Manitoba, Faculty of Science 1986 - 1988
Medical School:	University of Manitoba, Faculty of Medicine 1988 – 1992
Rotating Internship:	University of Ottawa, Ottawa Civic Hospital June 1992 – June 1993
Internal Medicine Residency:	University of Manitoba, Health Sciences Centre July 1993 – September 1995
Dermatology Residency:	University of Ottawa October 1995 – June 1998

ACADEMIC SCHOLARSHIPS & AWARDS

1986	Elizabeth Chown Scholarship
1992	Terry Meyers Scholarship
1998	Fisher Prize – American Contact Dermatology

PROFESSIONAL CERTIFICATIONS, DEGREES & MEMBERSHIPS

Basic Cardiac Life Support	1988, 1992
Advanced Cardiac Life Support	1992
Doctor of Medicine	1992
Licentiate of the Medical Council of Canada	1992
FLEX	1993
Chief Resident – Dermatology	1997-1998
Canadian Dermatology Fellowship	1998
American Dermatology Certification	1998
Manitoba Medical Association	current
Ontario Medical Association	current
College of Physicians and Surgeons of Manitoba	current
College of Physicians and Surgeons of Ontario	current
Royal College of Physicians and Surgeons of Canada	current
Canadian Medical Association	current
American Academy of Dermatology	current
Canadian Dermatology Association	current
President's Cup award- CDA	2013

COMMITTEES

Curriculum Evaluation	1988 – 1992
Internal Medicine Head Review	1991 – 1992
Social Representative	1988 – 1992
Graduation Committee	1991 – 1992
Ethics Meeting	1988 – 1995
Interns Association Treasurer	1992 – 1993
Undergraduate Committee	1993 – 1994
Chief Dermatology President	1997 – 1998
Dermatology Journal Club	1995 – present
Continuing Medical Education Committee	2000 – present
CDA – Membership and Awards Committee	2002 - present
Treasurer CDA	2005-2007
Treasurer CDA	2011-2013

PROFESSIONAL EXPERIENCE

Locum: Dr. James Walker Ste. 305-1919 Riverside Drive Ottawa, Ontario K1H 1A2	July 1998 – November 1998 July 1999 July 2000
Winnipeg Clinic First Glance Aesthetic Clinic The Derm Centre	November 1998 – 2013 2004-2013 February 2013 - present

VOLUNTEER WORK

Victoria Hospital Emergency	1986 – 1988
Peer Advisor/Councilor	1987 – 1988
Children's Hospital Research	1988 – 1992
CDA – Treasurer	
CDA Membership committee	
Royal College of Physicians and Surgeons Subspecialty Committee	
Manitoba Dermatology Working Group	

CLINICAL TEACHING

Ryan Zarychanski, medical student	August 23, 1999 – September 10, 1999
Marcie Ulmer, medical student	March 2003
Irena Turchin, medical student	March 2003
Many others	Ongoing

MEETINGS

Ottawa Dermatology Society	October 1995
American Academy of Dermatology	February 1996
Ottawa Dermatology Society	April 1996
Atlantic Dermatology Society	May 1996
Canadian Dermatology Association	July 1996
Ottawa Dermatology Society	October 1996
American Academy of Dermatology	March 1997
Ottawa Dermatology Society	April 1997
Atlantic Dermatology Society	May 1997
Canadian Dermatology Association	July 1997
Ottawa Dermatology Society	October 1997
American Academy of Dermatology	March 1998
Ottawa Dermatologic Society	April 1998
Canadian Dermatology Association	July 1998
American Academy of Dermatology	March 1999
Canadian Dermatology Association	July 2001
Canadian Dermatology Association	July 2003
Dermatology Update	October 2003
Therapeutic Strategies for the management of Atopic Dermatitis: Facilitation Training	January 2004
Elidel: Advancing Expectations in Atopic Eczema and Beyond	May 2004
CDA	Ongoing
AAD	Ongoing

PUBLICATIONS AND PRESENTATIONS

- The Ethnicity of Primary Biliary Cirrhosis
– Canadian Association of Gastroenterology Meeting, March 1995
- Terbinafine and Nail Hyperpigmentation
– Canadian Dermatology Association Meeting – July 1997
- Allergic Contact Dermatitis in Massage Therapists
– Allergic Contact Dermatitis Meeting March 1977
- Dispersed Blue Dye Dermatitis
– American Allergic Contact Dermatitis Meeting – March 1998
- Textile Dermatitis – Canadian Dermatology Association Meeting – July 1999
Textile Dermatitis – American Journal of Contact Dermatitis – to be published
- Acne treatment CME
Sponsored by Berlex – Nov 23, 2002
- Day in Dermatology CME
Cosmetic Dermatology March 2003

Mollusa, Warts, Actinic Keratosis CME
Sponsored by Berlex May 31, 2003

Acne Treatment CME
Sponsored by Berlex June 12, 2003

Atopic Dermatitis CME
Sponsored by Novartis June 19, 2003

New Treatment for Eczema, Manitoba Asian Physicians Conference
Sponsored by Novartis August 23, 2003

Psoriasis Review- Cyclosporine
Sponsored by Hoffman La Roche/ Leo November 15, 2003

Atopic Dermatitis Treatment
Sponsored by Fujisawa December 15, 2004

Atopic Dermatitis CME, Manitoba Clinic
Sponsored by Fujisawa January 21, 2004

Protopic: Atopic Dermatitis and More, Manitoba Clinic
Sponsored by Fujisawa January 26, 2004

Atopic Dermatitis CME, Assiniboine Clinic
Sponsored by Novartis January 29, 2004

Top Ten Dermatology Problems CME
Sponsored by Stiefeld January 29, 2004

Atopic Dermatitis CME, St. Boniface Clinic
Sponsored by Novartis February 4, 2004

Atopic Dermatitis Management, St. Boniface Clinic
Sponsored by Novartis February 12, 2004

Marketing Atopic Dermatitis Seminar
Sponsored by Novartis February 26, 2004

Top Ten Pediatric Dermatology Diseases, Manitoba Pediatric Society
Sponsored by Fujisawa March 15, 2004

Protopic Treatment Update, Manitoba Pediatric Society Meeting
Sponsored by Fujisawa April 15, 2004

Lichen Sclerosis and Lichen Planus, Manitoba Obstetrics and Gynecology Meeting
Sponsored by Fujisawa April 26, 2004

Atopic Dermatitis Case Studies, Family Physicians
Sponsored by Novartis June 8, 2004

Protopic in Atopic Dermatitis, Dr. Schellenburg and Family Doctors
Sponsored by Fujisawa. June 22, 2004

Many others until present

COMPLETED RESEARCH

- 2013 Esprit A 10 Year, Post-marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps). Principal Investigator: Dr. R P Haydey
- 2013 Observational Post-marketing Safety Surveillance Registry of Enbrel (etanercept) for the treatment of Psoriasis. Funded by: Amgen Canada Inc. Principal Investigator: Dr. R P Haydey
- 2013 A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50mg Once Weekly Plus As Needed Topical Agents Versus Etanercept 50mg Twice Weekly in Subjects with Moderate to Severe Plaque Psoriasis. Funded By: Amgen Canada Inc. Principal Investigator: Dr. Richard Haydey
- 2013 A Multicenter Study with a Randomized, Double-Blinded, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis. Funded By: Eli Lilly and Company Principal Investigator: Dr. VictoriaTaraska
- 2013 Psolar A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Funded By: Centocor Ortho Biotech Services Principal Investigator: Dr. R Haydey
- 2013 Effect of LEO 90100 on the HPA axis and Calcium Metabolism in Subjects with Extensive Psoriasis Vulgaris. Funded By: Leo Pharma A/S Principal Investigator: Dr. Victoria Taraska
- 2013 Align A Multi-Country, Cross Sectional Study to Determine Patient Specific and General Beliefs Towards Medication and Their Treatment Compliance to Selected Systemic Therapies in Chronic Inflammatory Diseases. Funded By: Abbott Laboratories Limited Principal Investigator: Dr. R. Haydey
- 2013 IPART Prognosis and Genetic Studies in Psoriasis and Psoriatic Arthritis. Principal Investigator: Dr. R. Haydey
- 2013 Inno-6017 Exploratory Study on Quality of Life in Patients with Moderate Psoriasis and Moderate Psoriatic Arthritis Funded By: Innovaderm Research Inc. Principal Investigator: Dr. R. Haydey

- 2013 Apples: A Prospective Pediatric Longitudinal Evaluation to Assess The Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. Funded By: Astellas Pharma Global Development, Inc. Principle Investigator: Dr. Jill Keddy-Grant
- 2012 AMAGINE-3 A Phase 3 Study to Evaluate the Efficacy and Safety Of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in AMAGINE-3. Funded By: Amgen Canada Inc. Principal Investigator: Dr. Haydey
- 2012 A Phase 3 Randomized, Double-blind, 12 Week Vehicle-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of CD5024 1% Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Follower by a 40-week Investigator-blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus Azelaic Acid 15% Gel. Funded By: Gladerma R&D Inc. Principal Investigator: Dr. R. P. Haydey
- 2012 M11-313 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa. Funded By: Abbott Principal Investigator: Dr. R. P. Haydey
- 2012 M12-555 A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa. Funded By: Abbott Principal Investigator: Dr. R.P Haydey
- 2012 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis. Funded By: Astellas Pharma Global Development, Inc. Principal Investigator: Dr. Victoria Taraska
- 2012 ATLAS Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS). Funded By: Astellas Pharma Canada Inc. Principal Investigator: Dr. Victoria Taraska
- 2012 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab. Funded By: Amgen Canada Inc. Principle Investigator: Dr. Richard Haydey
- 2012 Safety and Efficacy of Etanercept in Patients with Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory response to Adalimumab or Infliximab. Funded By: Innovaderm Research Inc. Principle investigator: Dr. Haydey
- 2012 A Multi-Center, Randomized, Double-Dummy, Double-Blind Study Evaluation Two Doses of Adalimumab Versus Methotrexate (MTX) in Pediatric Subjects with Chronic Plaque Psoriasis. Funded By: Abbott Principal Investigator: Dr. Jill Keddy-Grant
- 2012 Safety and Efficacy of Calcipotriol plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) with Scalp Psoriasis. Funded By: LEO Pharma. Principal Investigator: Dr. J. Keddy-Grant

- 2011 A.W.A.R.E-2 Amevive Wisdom Acquired through Real-World Evidence-2 (A.W.A.R.E.-2) Program: Long-Term. Funded By: Astellas Pharma Canada, Inc. Principal Investigator: Dr. Victoria Taraska
- 2011 A 5-Year, Multicenter, Open-Label, Parallel-Group, Randomized Study to Demonstrate the Short and Long Term Safety of Elidel(Pimecrolimus, ASM981) Cream 1% in the Treatment of Mild to Moderate Atopic Dermatitis in Infants (3 to less than 12 Months of Age). Funded By: Novartis. Principal Investigator: Dr. Jill Keddy-Grant
- 2011 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in subjects with Moderate to Severe Plaque Psoriasis. Principal Investigator: Dr. Victoria Taraska
- 2011 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing the Effectiveness in Psoriasis (Complete-Psoriasis). Funded By: Abbott. Principal Investigator: Dr. Jill Keddy- Grant
- 2011 Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects with Extensive Psoriasis Vulgari A Phase 2 Maximal use Systemic Exposer Study Involving the Safety and Efficacy of Calcipotriol 50mcg/g Plus Betamethasone 0.5mg/g (as Dipropionate) Gel Allied Once Daily in Subjects with Extensive Psoriasis Vulgaris on the Scalp and Non-Scalp Regions of the Body (truck and/or Limbs). Funded By: LEO 80185-G24. Principle Investigator: Dr. Victoria Taraska
- 2011 Prevalence of Psoriatic Arthritis in Adults with Psoriasis: An Estimate from Dermatology Practice. Principal Investigator: Dr. R. P. Haydey
- 2010 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients with Psoriasis Vulgaris. Funded By: Innovaderm Research Inc. Principal Investigator: Dr. Victoria Taraska
- 2010 A Phase 2 Study Evaluation the Safety and Efficacy of Calcipotriol 25 mcg/g Plus Hydrocortisone 10-mg/g Ointment Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and the Intertriginous Areas. Funded By: LEO 80190-023 Principal Investigator: Dr. R. Haydey
- 2010 Calcipotriol Plus Hydrocortisone in Pediatric Patients (Aged 6 to 17 Years) with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. Funded By: LEO 80190-025. Principal Investigator: Dr. Jill Keddy-Grant
- 2010 An Open-Label-Extension Study to Study MHE100185, to Evaluate Long-Term Safety, Efficacy and Optimal Dosing Frequency of 750mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndrome. Principle Investigator: Dr. Vince Taraska
- 2009 LEO 80190-022 "Calcipotriol plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. Funded By: LEO. Principal Investigator: DR. RP Haydey

- 2009 CAN-EASE (Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel in Psoriasis). Funded by: Amgen Canada Inc. Principle Investigator: Dr. R.P. Haydey
- 2007 A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE) Humera. Funded by Abbott, Site Principal Investigator: Dr. R P Haydey
- 2007 A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis. Funded by Novartis, Site Principal Investigator: Dr. Victoria Taraska
- 2006 A Phase IIa, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects with Moderate to Severe Plaque Psoriasis. Funded by Bristol-Myers Squibb, Site Principal Investigator: Dr. J. Keddy-Grant
- 2006 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Twice Daily Tacrolimus Cream-B 0.1% Versus Cream Vehicle in the Treatment of Psoriasis. Funded by Astellas, Site Principal Investigator: Dr. Victoria Taraska
- 2006 Herpes. Funded by GlaxoSmithKline, Site Principal Investigator: Dr. Victoria Taraska
- 2006 A Multi-Center, Randomized, Double-Blind, Parallel-Group Study To Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared with Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects with Acne Vulgaris. Funded by Galderma, Site Principal Investigator: Dr. R. P. Haydey
- 2006 CAN-EASE (Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel in Psoriasis). Funded by Amgen, Site Principal Investigator: Dr. R. P. Haydey
- 2006 Observational Post-marketing Safety Surveillance Registry of Enbrel® (etanercept) for the Treatment of Psoriasis. Funded by Amgen, Site Principal Investigator: Dr. R. P. Haydey
- 2006 Amevive Wisdom Acquired Through Real-Time Evidence (Aware) Program. Funded by Astellas, Site Principal Investigator: Dr. Victoria Taraska
- 2006 An Open-Label Randomized, Multicenter Study in Patients with Asthma to Evaluate the Effectiveness of ALVESCO™ (Ciclesonide) compared to Asthma usual care in A primary practice setting. Funded by Altana Pharma, Site Principal Investigators: Dr. Victoria Taraska
- 2005 A 16 week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use of a ASM 981 (pimecrolimus) cream 1% (BID) plus topical corticosteroid (BID) for the treatment of severe atopic dermatitis in patients 2 to 17 years of age. Funded by Novartis. Site Principal Investigator - Dr. V. Taraska

- 2005 A randomized, observer-blind, multicentre, non-inferiority, comparative, phase III study of the safety and efficacy of topical 1% SB-275833 ointment, applied twice daily for 5 days, versus topical 2% sodium fusidate ointment applied three times daily for 7 days in the treatment of adult and paediatric subjects with impetigo. Funded by GlaxoSmithKline. Site Principal Investigator – Dr. V. Taraska
- 2005 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients with Plaque Psoriasis (ISA05-02). Funded by Isotechnika Inc., Site Principal Investigator – Dr. V Taraska
- 2005 An open label, long-term extension study to assess the safety and efficacy of Etanercept in the treatment of psoriasis in adult subjects. Funded by Amgen Canada Inc., Site Principal Investigator – Dr. H. E. Murray
- 2005 A phase III, randomized, multicentre, double blind, placebo controlled study of ISA247 in plaque psoriasis patients (ISA04-03). Funded by Isotechnika Inc., Site Principal Investigator – Dr. V Taraska
- 2005 International Survey Evaluating microAlbuminuria Routinely by Cardiologists in patients with Hypertension. Funded by Bristol-Myers Squibb Company and Sanofi Aventis, Site principal investigators Dr. Victoria Taraska, Dr. Vince Taraska, Dr. N. Nagaria and Dr. L. Homik
- 2005 A phase IV study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment following treatment with combination ointment in psoriasis vulgaris. Funded by Leo Pharma Inc. Site Principal Investigator – Dr. V. Taraska
- 2005 A phase III study comparing a gel containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) with betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle and the gel vehicle alone, all applied once daily in the treatment of scalp psoriasis. Funded by Leo Pharma Inc. Site Principal Investigator – Dr. R.P. Haydey.
- 2005 A multicentre, randomized, double blind, placebo controlled phase III study of subcutaneously administered onercept in the treatment and re-treatment of subjects with moderate to severe plaque psoriasis. Funded by Serono, Inc. Site Principal Investigator – Dr. H. E. Murray
- 2004 An Open-label-extension Study to Study MHE100185, to Evaluate Long-term Safety, Efficacy and Optimal Dosing Frequency of 750mg Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndrome. Funded by GlaxoSmithKline Inc., Site Principal Investigator: Dr. Vince Taraska
- 2004 A randomized, investigator blinded, active-controlled, parallel-group study to compare the efficacy and safety of 6-week treatment with terbinafine new pediatric formulation versus 6-week treatment with griseofulvin pediatric suspension in children with Tinea capitis. Funded by Novartis, Site Principal Investigator – Dr. H.E. Murray

- 2004 A 5-year, multicenter, open-label, parallel-group, randomized study to demonstrate the short and long-term safety of Elidel (pimecrolimus, ASM981) cream 1% in the treatment of mild to moderate atopic dermatitis in infants (3 to less than 12 months of age). Funded by Novartis, Site Principal Investigator – Dr. J. Keddy-Grant
- 2004 BAP00089: Efficacy and safety of Alitretinoin in the treatment of severe chronic hand dermatitis refractory to topical therapy BAP00091: A double-blind, randomized, placebo-controlled, follow up efficacy and safety study of BAL4079 in the treatment of chronic hand dermatitis refractory to topical therapy. Funded by Basilea Pharmaceutica, Site Principal Investigator – Dr. R. P Haydey
- 2004 Phase II, Vehicle Cream Controlled, Double Blind, Randomized Study in Human, to evaluate the Safety and Efficacy of Fibrostat 0.8% (1,4 Diaminobutane Dihydrochloride) in the Inhibition of Hypertrophic Scar Formation due to Surgical or Thermal Insult. Funded by Procyon Biopharma Inc., Site Principal Investigator – Dr. R.P. Haydey
- 2003- 05 Etanercept 20030117 A Phase III Multicentre Study to Assess the Efficacy and Safety of Etanercept 50mg Twice Weekly in Psoriasis. Funded by Amgen. Site Principal Investigator – Dr. H. E. Murray
- 2003-05 A phase 3, long-term, open label study to evaluate the safety of once daily 0.3% tacrolimus gel, in the treatment of psoriasis. Funded by Fujisawa Canada. Inc., Site Principal Investigator – Dr. V. Taraska
- 2003-04 A 26-week, randomized, multicentre, parallel-group, double-blinded, controlled study to evaluate the incidence of atopic dermatitis flares when ASM981 (pimecrolimus) cream 1% is used at the first signs and/or symptoms of atopic dermatitis and it's safety and tolerability in adults 18 years of age and older. Funded by Novartis, Site Principal Investigator - Dr. J. Keddy- Grant vehicle
- 2003 -04 A Randomized, double-blind, placebo controlled, parallel group study to assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis. Funded by GlaxoSmithKline Inc., Site Principal Investigator - Dr. Eileen Murray
- 2003- 04 Etanercept 20030117 A Phase III Multicentre Study to Assess the Efficacy and Safety of Etanercept 50mg Twice Weekly in Psoriasis. Funded by Amgen, Principal Investigator- Dr. J. Toole
- 2003 Canadian, phase IV, open-label, multi-centre, study of Botox® (Botulinum Toxin Type A) for the Treatment of Patients with axillary hyperhidrosis. Funded by Allergan Canada
- 2003 An open-label, multi-centre study to evaluate the safety and tolerability of intramuscular administration of Alfacept (LFA-3/IgG Fusion Protein) in subjects with chronic plaque psoriasis who have completed studies C99-717 or C99-712. Funded by Biogen Incorporated
- 2003 A phase II study KH 1650 ointment 50µg/g, KH 1650 ointment 100 µg/g and KH 1650 ointment 200 µg /g with calcipotriol ointment 50 µg/g all applied once daily for 8 weeks in the treatment of psoriasis vulgaris. Funded by Leo Pharma Incorporated

- 2003 A multi-centre, single arm prospective, open label study to assess the safety of Elidel (SDZ AM 981- pimecrolimus) cream 1% in patients with atopic dermatitis. Funded by Novartis Pharmaceuticals Canada Incorporated
- 2003 A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multi- Centre Study Assessing the Effects of Norethindrone Acetate and Ethinyl Estradiol in the Improvement of Moderate to Severe Age Related Changes in Postmenopausal Women. Funded by Parke-Davis
- 2002 A multicentre controlled study of Cipamfylline ointment for the treatment of atopic dermatitis. Funded by Leo Pharma
- 2001-02 A randomized double blind placebo controlled dose – comparison study to evaluate the efficacy and safety of intramuscular administration of LFA3TIP in subjects with chronic plaque psoriasis. Funded by Biogen Incorporated
- 2001 A multicentre double blind placebo controlled study of Calcipotriol/Betamethasone Dipropionate once daily in psoriasis vulgaris. Funded by Leo Pharma
- 2001 An open label study to evaluate the safety of topically applied Tacrolimus ointment for treatment of atopic dermatitis. Funded by Fujisawa Canada Incorporated